MONTGOMERY, Ala.--(BUSINESS WIRE)--May 22, 2006--ProEthic Pharmaceuticals, Inc., a privately funded specialty pharmaceutical company that acquires, develops and markets niche prescription products, announced today that it has initiated a Phase III clinical trial for PRO-513, the company's product candidate for the treatment of migraine headaches. The study is being conducted under the guidance of a Special Protocol Assessment (SPA) provided by the U.S. Food and Drug Administration (FDA). The SPA indicates that if the trial successfully meets its primary endpoints, the data will provide the basis for an efficacy claim in a marketing application to the FDA.
